In addition to multiple methodological differences (formalin fixed paraffin embedded tissue versus serum, immunohistochemistry versus enzyme-linked immunosorbent assay (ELISA), subjective/semi-quantitative versus quantitative assessment, etc.)the angiogenic activity assessed by EGFL7 in situ may simply provide a better estimate of tumor responsiveness. Here, EGFL7 is linked to neoplasm.